Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase - PubMed
- ️Tue Jan 01 2008
. 2008 Jan 15;409(2):519-24.
doi: 10.1042/BJ20070681.
Affiliations
- PMID: 17877460
- DOI: 10.1042/BJ20070681
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
Jeffrey D Carson et al. Biochem J. 2008.
Abstract
The PIK3CA gene, encoding the p110alpha catalytic subunit of Class IA PI3Ks (phosphoinositide 3-kinases), is frequently mutated in many human tumours. The three most common tumour-derived alleles of p110alpha, H1047R, E542K and E545K, were shown to potently activate PI3K signalling in human epithelial cells. In the present study, we examine the biochemical activity of the recombinantly purified PI3K oncogenic mutants. The kinetic characterizations of the wt (wild-type) and the three 'hot spot' PI3K mutants show that the mutants all have approx. 2-fold increase in lipid kinase activities. Interestingly, the phosphorylated IRS-1 (insulin receptor substrate-1) protein shows activation of the lipid kinase activity for the wt and H1047R but not E542K and E545K PI3Kalpha, suggesting that these mutations represent different mechanisms of lipid kinase activation and hence transforming activity in cancer cells.
Similar articles
-
Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Stocking C, Bäsecke J. Horn S, et al. Oncogene. 2008 Jul 3;27(29):4096-106. doi: 10.1038/onc.2008.40. Epub 2008 Mar 3. Oncogene. 2008. PMID: 18317450
-
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Murugan AK, et al. Int J Oncol. 2008 Jan;32(1):101-11. Int J Oncol. 2008. PMID: 18097548
-
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. Huang CH, et al. Science. 2007 Dec 14;318(5857):1744-8. doi: 10.1126/science.1150799. Science. 2007. PMID: 18079394
-
Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
Vogt PK, Bader AG, Kang S. Vogt PK, et al. Virology. 2006 Jan 5;344(1):131-8. doi: 10.1016/j.virol.2005.09.027. Virology. 2006. PMID: 16364744 Review.
-
Oncogenic PI3K deregulates transcription and translation.
Bader AG, Kang S, Zhao L, Vogt PK. Bader AG, et al. Nat Rev Cancer. 2005 Dec;5(12):921-9. doi: 10.1038/nrc1753. Nat Rev Cancer. 2005. PMID: 16341083 Review.
Cited by
-
Genetic unraveling of colorectal cancer.
Rasool S, Rasool V, Naqvi T, Ganai BA, Shah BA. Rasool S, et al. Tumour Biol. 2014 Jun;35(6):5067-82. doi: 10.1007/s13277-014-1713-7. Epub 2014 Feb 27. Tumour Biol. 2014. PMID: 24573608 Review.
-
New perspectives in cancer drug development: computational advances with an eye to design.
Castelli M, Serapian SA, Marchetti F, Triveri A, Pirota V, Torielli L, Collina S, Doria F, Freccero M, Colombo G. Castelli M, et al. RSC Med Chem. 2021 Jul 7;12(9):1491-1502. doi: 10.1039/d1md00192b. eCollection 2021 Sep 23. RSC Med Chem. 2021. PMID: 34671733 Free PMC article. Review.
-
Rodríguez-Escudero I, Andrés-Pons A, Pulido R, Molina M, Cid VJ. Rodríguez-Escudero I, et al. J Biol Chem. 2009 May 15;284(20):13373-13383. doi: 10.1074/jbc.M807867200. Epub 2009 Mar 23. J Biol Chem. 2009. PMID: 19307184 Free PMC article.
-
Bian X, Dong W, Zhao Y, Sun R, Kong W, Li Y. Bian X, et al. J Mol Model. 2014 Apr;20(4):2166. doi: 10.1007/s00894-014-2166-z. Epub 2014 Mar 16. J Mol Model. 2014. PMID: 24633771
-
Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Burke JE, et al. Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259-64. doi: 10.1073/pnas.1205508109. Epub 2012 Sep 4. Proc Natl Acad Sci U S A. 2012. PMID: 22949682 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous